Sera Prognostics, a women's health company, reported a net loss of $7.9 million for Q3 2024, compared to a net loss of $7.2 million for Q3 2023. For the nine months ended September 30, 2024, the net loss was $24.3 million, a decrease from $28.3 million in the same period of 2023. Revenue for Q3 2024 was $29 thousand, down from $42 thousand in Q3 2023, while revenue for the nine-month period was $53 thousand, a decrease from $265 thousand in the previous year. Operating expenses for Q3 2024 totaled $8.891 million, up from $8.226 million in Q3 2023. The company has taken steps to reduce annual operating expenses and believes its cash runway is sufficient to operate into 2027. Sera Prognostics' business development has been focused on its PreTRM test, a blood-based biomarker test for predicting preterm birth risk. The company announced...Show More

Sera Prognostics, a women's health company, reported a net loss of $7.9 million for Q3 2024, compared to a net loss of $7.2 million for Q3 2023. For the nine months ended September 30, 2024, the net loss was $24.3 million, a decrease from $28.3 million in the same period of 2023. Revenue for Q3 2024 was $29 thousand, down from $42 thousand in Q3 2023, while revenue for the nine-month period was $53 thousand, a decrease from $265 thousand in the previous year. Operating expenses for Q3 2024 totaled $8.891 million, up from $8.226 million in Q3 2023. The company has taken steps to reduce annual operating expenses and believes its cash runway is sufficient to operate into 2027. Sera Prognostics' business development has been focused on its PreTRM test, a blood-based biomarker test for predicting preterm birth risk. The company announced positive results from the AVERT PRETERM TRIAL and the PRIME study, which demonstrated the test's efficacy and potential to reduce healthcare costs. Sera Prognostics is seeking publication of the PRIME study results and plans to launch real-world evidence implementation programs in late 2024 or early 2025. The company's future plans include expanding market adoption of the PreTRM test, developing additional biomarker tests, and improving test accessibility through whole-blood collection technologies.